

Shyam Sundar

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2388927/shyam-sundar-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

262
papers

15,086
citations

61
h-index

115
g-index

270
ext. papers

17,198
ext. citations

6.7
avg, IF

6.74
L-index

#	Paper	IF	Citations
262	Drug resistance in leishmaniasis. <i>Clinical Microbiology Reviews</i> , 2006 , 19, 111-26	34	1183
261	Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?. <i>Nature Reviews Microbiology</i> , 2007 , 5, 873-82	22.2	1047
260	Oral miltefosine for Indian visceral leishmaniasis. <i>New England Journal of Medicine</i> , 2002 , 347, 1739-46	59.2	543
259	Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. <i>Clinical Infectious Diseases</i> , 2000 , 31, 1104-7	11.6	499
258	Drug resistance in Indian visceral leishmaniasis. <i>Tropical Medicine and International Health</i> , 2001 , 6, 849-54	3	443
257	Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. <i>New England Journal of Medicine</i> , 1999 , 341, 1795-800	59.2	377
256	Antimony toxicity. <i>International Journal of Environmental Research and Public Health</i> , 2010 , 7, 4267-77	4.6	353
255	Whole genome sequencing of multiple <i>Leishmania donovani</i> clinical isolates provides insights into population structure and mechanisms of drug resistance. <i>Genome Research</i> , 2011 , 21, 2143-56	9.7	319
254	Injectable paromomycin for Visceral leishmaniasis in India. <i>New England Journal of Medicine</i> , 2007 , 356, 2571-81	59.2	312
253	Single-dose liposomal amphotericin B for visceral leishmaniasis in India. <i>New England Journal of Medicine</i> , 2010 , 362, 504-12	59.2	299
252	Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of <i>Leishmania donovani</i> . <i>Journal of Infectious Diseases</i> , 1999 , 180, 564-7	7	287
251	Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. <i>Journal of Experimental Medicine</i> , 2007 , 204, 805-17	16.6	260
250	Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. <i>Lancet, The</i> , 2011 , 377, 477-86	40	245
249	Trial of oral miltefosine for visceral leishmaniasis. <i>Lancet, The</i> , 1998 , 352, 1821-3	40	205
248	Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. <i>Clinical Infectious Diseases</i> , 2012 , 55, 543-50	11.6	198
247	Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. <i>Journal of Infectious Diseases</i> , 2007 , 196, 591-8	7	194
246	Leishmaniasis: an update of current pharmacotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 53-63	4	183

245	Laboratory diagnosis of visceral leishmaniasis. <i>Vaccine Journal</i> , 2002 , 9, 951-8		180
244	An update on pharmacotherapy for leishmaniasis. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 237-52	4	171
243	New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. <i>Clinical Infectious Diseases</i> , 2008 , 47, 1000-6	11.6	158
242	Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. <i>Clinical Infectious Diseases</i> , 2004 , 38, 377-83	11.6	141
241	Serial quantitative PCR assay for detection, species discrimination, and quantification of <i>Leishmania</i> spp. in human samples. <i>Journal of Clinical Microbiology</i> , 2011 , 49, 3892-904	9.7	128
240	IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. <i>Journal of Infectious Diseases</i> , 2011 , 204, 1134-7	7	128
239	Visceral leishmaniasis in the Indian subcontinent: modelling epidemiology and control. <i>PLoS Neglected Tropical Diseases</i> , 2011 , 5, e1405	4.8	125
238	Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. <i>BMJ: British Medical Journal</i> , 2001 , 323, 419-22		120
237	Short-course of oral miltefosine for treatment of visceral leishmaniasis. <i>Clinical Infectious Diseases</i> , 2000 , 31, 1110-3	11.6	120
236	Incidence of symptomatic and asymptomatic <i>Leishmania donovani</i> infections in high-endemic foci in India and Nepal: a prospective study. <i>PLoS Neglected Tropical Diseases</i> , 2011 , 5, e1284	4.8	118
235	IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis. <i>Journal of Immunology</i> , 2011 , 186, 3977-85	5.3	115
234	Splenic cytokine responses in Indian kala-azar before and after treatment. <i>Journal of Infectious Diseases</i> , 1998 , 177, 815-8	7	113
233	A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. <i>Vaccine</i> , 2011 , 29, 3531-7	4.1	111
232	Asymptomatic <i>Leishmania</i> infection: a new challenge for <i>Leishmania</i> control. <i>Clinical Infectious Diseases</i> , 2014 , 58, 1424-9	11.6	107
231	Evolutionary genomics of epidemic visceral leishmaniasis in the Indian subcontinent. <i>ELife</i> , 2016 , 5,	8.9	107
230	Liposomal amphotericin B and leishmaniasis: dose and response. <i>Journal of Global Infectious Diseases</i> , 2010 , 2, 159-66	2.8	103
229	Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. <i>American Journal of Tropical Medicine and Hygiene</i> , 1997 , 56, 522-5	3.2	103
228	Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. <i>Parasitology Research</i> , 2005 , 96, 216-23	2.4	101

227	Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective. <i>Infectious Diseases of Poverty</i> , 2016 , 5, 19	10.4	100
226	Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. <i>Journal of Infectious Diseases</i> , 1997 , 176, 1117-9	7	93
225	Advances in the treatment of leishmaniasis. <i>Current Opinion in Infectious Diseases</i> , 2002 , 15, 593-8	5.4	92
224	CD8 T cell exhaustion in human visceral leishmaniasis. <i>Journal of Infectious Diseases</i> , 2014 , 209, 290-9	7	91
223	Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. <i>PLoS Neglected Tropical Diseases</i> , 2012 , 6, e1657	4.8	86
222	Recent developments and future prospects in the treatment of visceral leishmaniasis. <i>Therapeutic Advances in Infectious Disease</i> , 2016 , 3, 98-109	2.8	80
221	Longlasting insecticidal nets for prevention of Leishmania donovani infection in India and Nepal: paired cluster randomised trial. <i>BMJ, The</i> , 2010 , 341, c6760	5.9	80
220	Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood. <i>Vaccine Journal</i> , 2012 , 19, 961-6		79
219	Availability of miltefosine for the treatment of kala-azar in India. <i>Bulletin of the World Health Organization</i> , 2005 , 83, 394-5	8.2	79
218	Interventions for visceral leishmaniasis. <i>The Cochrane Library</i> , 2017 ,	5.2	78
217	A PHASE II DOSE-RANGING STUDY OF SITAMAQUINE FOR THE TREATMENT OF VISCERAL LEISHMANIASIS IN INDIA. <i>American Journal of Tropical Medicine and Hygiene</i> , 2005 , 73, 1005-1011	3.2	78
216	Elimination of visceral leishmaniasis on the Indian subcontinent. <i>Lancet Infectious Diseases, The</i> , 2016 , 16, e304-e309	25.5	78
215	Oral miltefosine for the treatment of Indian visceral leishmaniasis. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2006 , 100 Suppl 1, S26-33	2	77
214	Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis. <i>Nature Genetics</i> , 2013 , 45, 208-13	36.3	76
213	Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. <i>Annals of Internal Medicine</i> , 1997 , 127, 133-7	8	71
212	Treatment of visceral leishmaniasis. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 2821-9	4	70
211	Rapid, noninvasive diagnosis of visceral leishmaniasis in India: comparison of two immunochromatographic strip tests for detection of anti-K39 antibody. <i>Journal of Clinical Microbiology</i> , 2006 , 44, 251-3	9.7	68
210	Evaluation of rapid diagnostic tests: visceral leishmaniasis. <i>Nature Reviews Microbiology</i> , 2007 , 5, S31-S39	2.2	67

209	Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis. <i>Journal of Infectious Diseases</i> , 1995 , 171, 992-6	7	67
208	Paromomycin in the treatment of leishmaniasis. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 787-94	5.9	66
207	Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions. <i>Clinical Infectious Diseases</i> , 2007 , 45, 556-61	11.6	66
206	Chemotherapeutics of visceral leishmaniasis: present and future developments. <i>Parasitology</i> , 2018 , 145, 481-489	2.7	65
205	Current and emerging medications for the treatment of leishmaniasis. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 1251-1265	4	63
204	Nano-structured nickel oxide based DNA biosensor for detection of visceral leishmaniasis (Kala-azar). <i>Analyst, The</i> , 2011 , 136, 2845-51	5	62
203	Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects. <i>Frontiers in Immunology</i> , 2014 , 5, 296	8.4	61
202	Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. <i>Pediatric Infectious Disease Journal</i> , 2003 , 22, 434-8	3.4	61
201	Blimp-1-Dependent IL-10 Production by Tr1 Cells Regulates TNF-Mediated Tissue Pathology. <i>PLoS Pathogens</i> , 2016 , 12, e1005398	7.6	57
200	Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia. <i>PLoS ONE</i> , 2014 , 9, e100220	3.7	55
199	Elongation factor-2, a Th1 stimulatory protein of <i>Leishmania donovani</i> , generates strong IFN- γ and IL-12 response in cured <i>Leishmania</i> -infected patients/hamsters and protects hamsters against <i>Leishmania</i> challenge. <i>Journal of Immunology</i> , 2011 , 187, 6417-27	5.3	55
198	Elucidation of cellular mechanisms involved in experimental paromomycin resistance in <i>Leishmania donovani</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 2580-5	5.9	54
197	Strong association between serological status and probability of progression to clinical visceral leishmaniasis in prospective cohort studies in India and Nepal. <i>PLoS Neglected Tropical Diseases</i> , 2014 , 8, e2657	4.8	53
196	DETECTION OF LEISHMANIAL ANTIGEN IN THE URINE OF PATIENTS WITH VISCERAL LEISHMANIASIS BY A LATEX AGGLUTINATION TEST. <i>American Journal of Tropical Medicine and Hygiene</i> , 2005 , 73, 269-271	3.2	53
195	Diagnosis of Indian visceral leishmaniasis by nucleic acid detection using PCR. <i>PLoS ONE</i> , 2011 , 6, e19304	3.7	52
194	Molecular Diagnosis of Visceral Leishmaniasis. <i>Molecular Diagnosis and Therapy</i> , 2018 , 22, 443-457	4.5	52
193	Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study. <i>The Lancet Global Health</i> , 2014 , 2, e51-7	13.6	51
192	Developments in Diagnosis of Visceral Leishmaniasis in the Elimination Era. <i>Journal of Parasitology Research</i> , 2015 , 2015, 239469	1.9	50

191	VIRGIN SOIL: THE SPREAD OF VISCERAL LEISHMANIASIS INTO UTTAR PRADESH, INDIA. <i>American Journal of Tropical Medicine and Hygiene</i> , 2005 , 73, 720-725	3.2	50
190	Cytokine responses to novel antigens in an Indian population living in an area endemic for visceral leishmaniasis. <i>PLoS Neglected Tropical Diseases</i> , 2012 , 6, e1874	4.8	49
189	Differential Expression of miRNA Regulates T Cell Differentiation and Plasticity During Visceral Leishmaniasis Infection. <i>Frontiers in Microbiology</i> , 2016 , 7, 206	5.7	49
188	Understanding the transmission dynamics of <i>Leishmania donovani</i> to provide robust evidence for interventions to eliminate visceral leishmaniasis in Bihar, India. <i>Parasites and Vectors</i> , 2016 , 9, 25	4	47
187	Increased miltefosine tolerance in clinical isolates of <i>Leishmania donovani</i> is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress. <i>PLoS Neglected Tropical Diseases</i> , 2017 , 11, e0005641	4.8	46
186	<i>Leishmania</i> specific CD4 T cells release IFN γ that limits parasite replication in patients with visceral leishmaniasis. <i>PLoS Neglected Tropical Diseases</i> , 2014 , 8, e3198	4.8	46
185	Molecular Docking and in Vitro Antileishmanial Evaluation of Chromene-2-thione Analogues. <i>ACS Medicinal Chemistry Letters</i> , 2012 , 3, 243-7	4.3	44
184	Latent infection with <i>Leishmania donovani</i> in highly endemic villages in Bihar, India. <i>PLoS Neglected Tropical Diseases</i> , 2013 , 7, e2053	4.8	43
183	Heterogeneity of <i>Leishmania donovani</i> parasites complicates diagnosis of visceral leishmaniasis: comparison of different serological tests in three endemic regions. <i>PLoS ONE</i> , 2015 , 10, e0116408	3.7	42
182	Interferon-gamma release assay (modified QuantiFERON) as a potential marker of infection for <i>Leishmania donovani</i> , a proof of concept study. <i>PLoS Neglected Tropical Diseases</i> , 2011 , 5, e1042	4.8	42
181	Febrifugine analogues as <i>Leishmania donovani</i> trypanothione reductase inhibitors: binding energy analysis assisted by molecular docking, ADMET and molecular dynamics simulation. <i>Journal of Biomolecular Structure and Dynamics</i> , 2017 , 35, 141-158	3.6	41
180	NADH-oxidase, NADPH-oxidase and myeloperoxidase activity of visceral leishmaniasis patients. <i>Journal of Medical Microbiology</i> , 2002 , 51, 832-836	3.2	41
179	Comparative evaluation of freeze-dried and liquid antigens in the direct agglutination test for serodiagnosis of visceral leishmaniasis (ITMA-DAT/VL). <i>Tropical Medicine and International Health</i> , 2006 , 11, 1777-84	2.3	39
178	Treatment of visceral leishmaniasis. <i>Medical Microbiology and Immunology</i> , 2001 , 190, 89-92	4	39
177	KNOWLEDGE, ATTITUDE, AND PRACTICES RELATED TO KALA-AZAR IN A RURAL AREA OF BIHAR STATE, INDIA. <i>American Journal of Tropical Medicine and Hygiene</i> , 2006 , 75, 505-508	3.2	39
176	Virgin soil: the spread of visceral leishmaniasis into Uttar Pradesh, India. <i>American Journal of Tropical Medicine and Hygiene</i> , 2005 , 73, 720-5	3.2	39
175	Investigational drugs for visceral leishmaniasis. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 43-59	5.9	38
174	Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment. <i>Clinical Infectious Diseases</i> , 2009 , 49, 914-8	11.6	38

173	Oral miltefosine for Indian post-kala-azar dermal leishmaniasis: a randomised trial. <i>Tropical Medicine and International Health</i> , 2013 , 18, 96-100	2.3	37
172	Visceral leishmaniasis in Muzaffarpur district, Bihar, India from 1990 to 2008. <i>PLoS ONE</i> , 2011 , 6, e147513	3.7	37
171	Characterization of glycolytic enzymes--rAldolase and rEnolase of <i>Leishmania donovani</i> , identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasis. <i>PLoS ONE</i> , 2014 , 9, e86073	3.7	36
170	IgG1 as a potential biomarker of post-chemotherapeutic relapse in visceral leishmaniasis, and adaptation to a rapid diagnostic test. <i>PLoS Neglected Tropical Diseases</i> , 2014 , 8, e3273	4.8	36
169	Drug targeting to infectious diseases by nanoparticles surface functionalized with special biomolecules. <i>Current Medicinal Chemistry</i> , 2012 , 19, 3196-202	4.3	36
168	Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study. <i>PLoS Neglected Tropical Diseases</i> , 2014 , 8, e3169	4.8	35
167	Visceral leishmaniasis in rural bihar, India. <i>Emerging Infectious Diseases</i> , 2012 , 18, 1662-4	10.2	35
166	Evaluation of blood agar microtiter plates for culturing leishmania parasites to titrate parasite burden in spleen and peripheral blood of patients with visceral leishmaniasis. <i>Journal of Clinical Microbiology</i> , 2010 , 48, 1932-4	9.7	35
165	Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?. <i>Nature Reviews Microbiology</i> , 2007 , 5, S7-S16	22.2	35
164	Developing imidazole analogues as potential inhibitor for <i>Leishmania donovani</i> trypanothione reductase: virtual screening, molecular docking, dynamics and ADMET approach. <i>Journal of Biomolecular Structure and Dynamics</i> , 2015 , 33, 2541-53	3.6	34
163	Single-dose indigenous liposomal amphotericin B in the treatment of Indian visceral leishmaniasis: a phase 2 study. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015 , 92, 513-7	3.2	34
162	Mannose-conjugated curcumin-chitosan nanoparticles: Efficacy and toxicity assessments against <i>Leishmania donovani</i> . <i>International Journal of Biological Macromolecules</i> , 2018 , 111, 109-120	7.9	34
161	Model-based investigations of different vector-related intervention strategies to eliminate visceral leishmaniasis on the Indian subcontinent. <i>PLoS Neglected Tropical Diseases</i> , 2014 , 8, e2810	4.8	34
160	Evaluation of <i>Leishmania donovani</i> protein disulfide isomerase as a potential immunogenic protein/vaccine candidate against visceral Leishmaniasis. <i>PLoS ONE</i> , 2012 , 7, e35670	3.7	34
159	Structure-based virtual screening, molecular docking, ADMET and molecular simulations to develop benzoxaborole analogs as potential inhibitor against <i>Leishmania donovani</i> trypanothione reductase. <i>Journal of Receptor and Signal Transduction Research</i> , 2017 , 37, 60-70	2.6	33
158	Quantitative PCR in epidemiology for early detection of visceral leishmaniasis cases in India. <i>PLoS Neglected Tropical Diseases</i> , 2014 , 8, e3366	4.8	33
157	Strategies to overcome antileishmanial drugs unresponsiveness. <i>Journal of Tropical Medicine</i> , 2014 , 2014, 646932	2.4	33
156	High-throughput virtual screening and quantum mechanics approach to develop imipramine analogues as leads against trypanothione reductase of leishmania. <i>Biomedicine and Pharmacotherapy</i> , 2016 , 83, 141-152	7.5	32

155	Longitudinal Seroepidemiologic Study of Visceral Leishmaniasis in Hyperendemic Regions of Bihar, India. <i>American Journal of Tropical Medicine and Hygiene</i> , 2009 , 80, 345-346	3.2	32
154	Phase 4 pharmacovigilance trial of paromomycin injection for the treatment of visceral leishmaniasis in India. <i>Journal of Tropical Medicine</i> , 2011 , 2011, 645203	2.4	31
153	Evaluation of the direct agglutination test as an immunodiagnostic tool for kala-azar in India. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1993 , 87, 276-8	2	31
152	Arsenic exposure and outcomes of antimonial treatment in visceral leishmaniasis patients in Bihar, India: a retrospective cohort study. <i>PLoS Neglected Tropical Diseases</i> , 2015 , 9, e0003518	4.8	30
151	Visceral leishmaniasis elimination targets in India, strategies for preventing resurgence. <i>Expert Review of Anti-Infective Therapy</i> , 2018 , 16, 805-812	5.5	30
150	A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. <i>American Journal of Tropical Medicine and Hygiene</i> , 2005 , 73, 1005-11	3.2	30
149	Induction of Th1-type cellular responses in cured/exposed Leishmania-infected patients and hamsters against polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa. <i>Vaccine</i> , 2008 , 26, 4813-8	4.1	29
148	Knowledge, attitude, and practices related to Kala-azar in a rural area of Bihar state, India. <i>American Journal of Tropical Medicine and Hygiene</i> , 2006 , 75, 505-8	3.2	29
147	Longitudinal seroepidemiologic study of visceral leishmaniasis in hyperendemic regions of Bihar, India. <i>American Journal of Tropical Medicine and Hygiene</i> , 2009 , 80, 345-6	3.2	29
146	Determinants for progression from asymptomatic infection to symptomatic visceral leishmaniasis: A cohort study. <i>PLoS Neglected Tropical Diseases</i> , 2019 , 13, e0007216	4.8	28
145	Emerging therapeutic targets for treatment of leishmaniasis. <i>Expert Opinion on Therapeutic Targets</i> , 2018 , 22, 467-486	6.4	28
144	Significantly lower anti-Leishmania IgG responses in Sudanese versus Indian visceral leishmaniasis. <i>PLoS Neglected Tropical Diseases</i> , 2014 , 8, e2675	4.8	28
143	Parasite load estimation by qPCR differentiates between asymptomatic and symptomatic infection in Indian visceral leishmaniasis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014 , 80, 40-2	2.9	27
142	Efficacy and safety of miltefosine in treatment of post-kala-azar dermal leishmaniasis. <i>Scientific World Journal, The</i> , 2015 , 2015, 414378	2.2	27
141	Seasonal variation in the prevalence of sand flies infected with Leishmania donovani. <i>PLoS ONE</i> , 2013 , 8, e61370	3.7	27
140	Evaluation of ex vivo human immune response against candidate antigens for a visceral leishmaniasis vaccine. <i>American Journal of Tropical Medicine and Hygiene</i> , 2010 , 82, 808-13	3.2	27
139	Detection of leishmanial antigen in the urine of patients with visceral leishmaniasis by a latex agglutination test. <i>American Journal of Tropical Medicine and Hygiene</i> , 2005 , 73, 269-71	3.2	27
138	Ambisome plus miltefosine for Indian patients with kala-azar. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2011 , 105, 115-7	2	26

137	Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis. <i>Scientific Reports</i> , 2020 , 10, 12243	4.9	26
136	Imipramine exploits histone deacetylase 11 to increase the IL-12/IL-10 ratio in macrophages infected with antimony-resistant <i>Leishmania donovani</i> and clears organ parasites in experimental infection. <i>Journal of Immunology</i> , 2014 , 193, 4083-94	5.3	25
135	Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2006 , 100, 698-700	2	25
134	In vitro and in vivo evaluation of anti-leishmanial and immunomodulatory activity of Neem leaf extract in <i>Leishmania donovani</i> infection. <i>Experimental Parasitology</i> , 2015 , 153, 45-54	2.1	24
133	Immune Checkpoint Targets for Host-Directed Therapy to Prevent and Treat Leishmaniasis. <i>Frontiers in Immunology</i> , 2017 , 8, 1492	8.4	24
132	The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation. <i>Nature Immunology</i> , 2020 , 21, 1205-1218	19.1	24
131	Antimony-Resistant <i>Leishmania donovani</i> Exploits miR-466i To Deactivate Host MyD88 for Regulating IL-10/IL-12 Levels during Early Hours of Infection. <i>Journal of Immunology</i> , 2015 , 195, 2731-42	5.3	23
130	Outcome of patients on second line antiretroviral therapy under programmatic condition in India. <i>BMC Infectious Diseases</i> , 2015 , 15, 517	4	23
129	Amplified fragment length polymorphism (AFLP) analysis is useful for distinguishing <i>Leishmania</i> species of visceral and cutaneous forms. <i>Acta Tropica</i> , 2010 , 113, 202-6	3.2	23
128	Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis. <i>Clinical Infectious Diseases</i> , 2006 , 42, 608-13	11.6	22
127	Validation of SYBR green I based closed tube loop mediated isothermal amplification (LAMP) assay and simplified direct-blood-lysis (DBL)-LAMP assay for diagnosis of visceral leishmaniasis (VL). <i>PLoS Neglected Tropical Diseases</i> , 2018 , 12, e0006922	4.8	22
126	Visceral leishmaniasis: Spatiotemporal heterogeneity and drivers underlying the hotspots in Muzaffarpur, Bihar, India. <i>PLoS Neglected Tropical Diseases</i> , 2018 , 12, e0006888	4.8	22
125	Type I Interferons Suppress Anti-parasitic Immunity and Can Be Targeted to Improve Treatment of Visceral Leishmaniasis. <i>Cell Reports</i> , 2020 , 30, 2512-2525.e9	10.6	21
124	Antimony resistant <i>Leishmania donovani</i> but not sensitive ones drives greater frequency of potent T-regulatory cells upon interaction with human PBMCs: role of IL-10 and TGF- β in early immune response. <i>PLoS Neglected Tropical Diseases</i> , 2014 , 8, e2995	4.8	21
123	Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India. <i>Tropical Medicine and International Health</i> , 2012 , 17, 1345-8	2.3	21
122	Genetic markers for SSG resistance in <i>Leishmania donovani</i> and SSG treatment failure in visceral leishmaniasis patients of the Indian subcontinent. <i>Journal of Infectious Diseases</i> , 2012 , 206, 752-5	7	21
121	A Subset of Neutrophils Expressing Markers of Antigen-Presenting Cells in Human Visceral Leishmaniasis. <i>Journal of Infectious Diseases</i> , 2016 , 214, 1531-1538	7	21
120	Leishmaniasis: treatment, drug resistance and emerging therapies. <i>Expert Opinion on Orphan Drugs</i> , 2019 , 7, 1-10	1.1	21

119	Recent advances in the diagnosis and treatment of kala-azar. <i>The National Medical Journal of India</i> , 2012 , 25, 85-9	0.4	21
118	Investments in Research and Surveillance Are Needed to Go Beyond Elimination and Stop Transmission of Leishmania in the Indian Subcontinent. <i>PLoS Neglected Tropical Diseases</i> , 2017 , 11, e0005190	4.8	20
117	A novel recombinant Leishmania donovani p45, a partial coding region of methionine aminopeptidase, generates protective immunity by inducing a Th1 stimulatory response against experimental visceral leishmaniasis. <i>International Journal for Parasitology</i> , 2012 , 42, 429-35	4.3	20
116	Comparative proteomics and glycoproteomics of plasma proteins in Indian visceral leishmaniasis. <i>Proteome Science</i> , 2014 , 12, 48	2.6	20
115	Diagnostic PCR with Leishmania donovani specificity using sequences from the variable region of kinetoplast minicircle DNA. <i>Tropical Medicine and International Health</i> , 1999 , 4, 448-53	2.3	20
114	Molecular typing of HLA class I and class II antigens in Indian kala-azar patients. <i>Tropical Medicine and International Health</i> , 1997 , 2, 468-471	2.3	19
113	Th1 stimulatory proteins of Leishmania donovani: comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis. <i>PLoS ONE</i> , 2014 , 9, e108556	3.7	19
112	Xenodiagnosis to evaluate the infectiousness of humans to sandflies in an area endemic for visceral leishmaniasis in Bihar, India: a transmission-dynamics study. <i>Lancet Microbe, The</i> , 2021 , 2, e23-e31	22.2	19
111	Voacamine alters Leishmania ultrastructure and kills parasite by poisoning unusual bi-subunit topoisomerase IB. <i>Biochemical Pharmacology</i> , 2017 , 138, 19-30	6	18
110	Iron superoxide dismutase contributes to miltefosine resistance in Leishmania donovani. <i>FEBS Journal</i> , 2019 , 286, 3488-3503	5.7	18
109	Arsenic, antimony, and Leishmania: has arsenic contamination of drinking water in India led to treatment-resistant kala-azar?. <i>Lancet, The</i> , 2015 , 385 Suppl 1, S80	4.0	18
108	Post kala-azar dermal leishmaniasis: A threat to elimination program. <i>PLoS Neglected Tropical Diseases</i> , 2020 , 14, e0008221	4.8	18
107	Exposure to Phlebotomus argentipes (Diptera, Phlebotomidae, Phlebotominae) sand flies in rural areas of Bihar, India: the role of housing conditions. <i>PLoS ONE</i> , 2014 , 9, e106771	3.7	18
106	Pharmacokinetics of oral sitamaquine taken with or without food and safety and efficacy for treatment of visceral leishmaniasis: a randomized study in Bihar, India. <i>American Journal of Tropical Medicine and Hygiene</i> , 2011 , 84, 892-900	3.2	18
105	Nucleosomal histone proteins of L. donovani: a combination of recombinant H2A, H2B, H3 and H4 proteins were highly immunogenic and offered optimum prophylactic efficacy against Leishmania challenge in hamsters. <i>PLoS ONE</i> , 2014 , 9, e97911	3.7	18
104	Whole blood assay and visceral leishmaniasis: Challenges and promises. <i>Immunobiology</i> , 2014 , 219, 323-8	3.4	17
103	Phenotypic and functional characteristics of HLA-DR neutrophils in Brazilians with cutaneous leishmaniasis. <i>Journal of Leukocyte Biology</i> , 2017 , 101, 739-749	6.5	17
102	Meta-taxonomic analysis of prokaryotic and eukaryotic gut flora in stool samples from visceral leishmaniasis cases and endemic controls in Bihar State India. <i>PLoS Neglected Tropical Diseases</i> , 2019 , 13, e0007444	4.8	16

101	Proteomic analyses of membrane enriched proteins of Leishmania donovani Indian clinical isolate by mass spectrometry. <i>Parasitology International</i> , 2015 , 64, 36-42	2.1	16
100	Envisioning the innovations in nanomedicine to combat visceral leishmaniasis: for future theranostic application. <i>Nanomedicine</i> , 2019 , 14, 1911-1927	5.6	16
99	Visceral Leishmaniasis IgG1 Rapid Monitoring of Cure vs. Relapse, and Potential for Diagnosis of Post Kala-Azar Dermal Leishmaniasis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2018 , 8, 427	5.9	16
98	Visceral leishmaniasis. <i>Tropical Parasitology</i> , 2015 , 5, 83-5	0.4	15
97	-Induced Increase in Macrophage Bcl-2 Favors Parasite Survival. <i>Frontiers in Immunology</i> , 2016 , 7, 456	8.4	15
96	Leptomonas seymouri narna-like virus 1 and not leishmaniaviruses detected in kala-azar samples from India. <i>Archives of Virology</i> , 2017 , 162, 3827-3835	2.6	14
95	Wnt5a Signaling Promotes Host Defense against Infection. <i>Journal of Immunology</i> , 2017 , 199, 992-1002	5.3	14
94	Failure of ketoconazole treatment in cutaneous leishmaniasis. <i>International Journal of Dermatology</i> , 1995 , 34, 120-1	1.7	14
93	Detection of Immunoglobulin G1 Against rK39 Improves Monitoring of Treatment Outcomes in Visceral Leishmaniasis. <i>Clinical Infectious Diseases</i> , 2019 , 69, 1130-1135	11.6	14
92	Immunogenicity and Protective Efficacy of T-Cell Epitopes Derived From Potential Th1 Stimulatory Proteins of. <i>Frontiers in Immunology</i> , 2019 , 10, 288	8.4	13
91	Characterization of the proliferating cell nuclear antigen of Leishmania donovani clinical isolates and its association with antimony resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 2997-3007	5.9	13
90	Establishing, Expanding, and Certifying a Closed Colony of Phlebotomus argentipes (Diptera: Psychodidae) for Xenodiagnostic Studies at the Kala Azar Medical Research Center, Muzaffarpur, Bihar, India. <i>Journal of Medical Entomology</i> , 2017 , 54, 1129-1139	2.2	13
89	Prevalence of sand flies and Leishmania donovani infection in a natural population of female Phlebotomus argentipes in Bihar State, India. <i>Vector-Borne and Zoonotic Diseases</i> , 2012 , 12, 467-72	2.4	13
88	Diagnostic and prognostic potential of a competitive enzyme-linked immunosorbent assay for leishmaniasis in India. <i>Vaccine Journal</i> , 1999 , 6, 550-4		13
87	Xenodiagnosis to address key questions in visceral leishmaniasis control and elimination. <i>PLoS Neglected Tropical Diseases</i> , 2020 , 14, e0008363	4.8	13
86	Inflammatory chemokines and their receptors in human visceral leishmaniasis: Gene expression profile in peripheral blood, splenic cellular sources and their impact on trafficking of inflammatory cells. <i>Molecular Immunology</i> , 2017 , 85, 111-119	4.3	12
85	Long-lasting insecticidal nets to prevent visceral leishmaniasis in the Indian subcontinent; methodological lessons learned from a cluster randomised controlled trial. <i>PLoS Neglected Tropical Diseases</i> , 2015 , 9, e0003597	4.8	12
84	Male predominance in reported Visceral Leishmaniasis cases: Nature or nurture? A comparison of population-based with health facility-reported data. <i>PLoS Neglected Tropical Diseases</i> , 2020 , 14, e0007995	4.8	12

83	Understanding Leishmania parasites through proteomics and implications for the clinic. <i>Expert Review of Proteomics</i> , 2018 , 15, 371-390	4.2	12
82	Peripheral Blood Monocytes With an Antiinflammatory Phenotype Display Limited Phagocytosis and Oxidative Burst in Patients With Visceral Leishmaniasis. <i>Journal of Infectious Diseases</i> , 2018 , 218, 1130-1141	7	12
81	Characterization and evaluation of amine-modified graphene amphotericin B for the treatment of visceral leishmaniasis: in vivo and in vitro studies. <i>Drug Design, Development and Therapy</i> , 2014 , 8, 1235-474	4.4	12
80	Formulation, characterization and in vitro anti-leishmanial evaluation of amphotericin B loaded solid lipid nanoparticles coated with vitamin B-stearic acid conjugate. <i>Materials Science and Engineering C</i> , 2020 , 117, 111279	8.3	12
79	Diagnosis and treatment of Indian visceral leishmaniasis. <i>Journal of the Association of Physicians of India, The</i> , 2003 , 51, 195-201	0.4	12
78	Transcriptome profiling identifies genes/pathways associated with experimental resistance to paromomycin in <i>Leishmania donovani</i> . <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2017 , 7, 370-377	4	11
77	Visceral Leishmaniasis-Optimum Treatment Options in Children. <i>Pediatric Infectious Disease Journal</i> , 2018 , 37, 492-494	3.4	11
76	Functional Involvement of <i>Leishmania donovani</i> Tryparedoxin Peroxidases during Infection and Drug Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	11
75	Transcriptional blood signatures for active and amphotericin B treated visceral leishmaniasis in India. <i>PLoS Neglected Tropical Diseases</i> , 2019 , 13, e0007673	4.8	11
74	Alcoholic Fractions F5 and F6 from Leaves Show a Potent Antileishmanial and Immunomodulatory Activities to Control Experimental Visceral Leishmaniasis. <i>Frontiers in Medicine</i> , 2017 , 4, 55	4.9	11
73	Morphological and Genotypic Variations among the Species of the Subgenus <i>Adlerius</i> (Diptera: Psychodidae, Phlebotomus) in Iran. <i>Journal of Arthropod-Borne Diseases</i> , 2015 , 9, 84-97	0.8	11
72	Evaluation of Safety and Antileishmanial Efficacy of Amine Functionalized Carbon-Based Composite Nanoparticle Appended With Amphotericin B: An and Preclinical Study. <i>Frontiers in Chemistry</i> , 2020 , 8, 510	5	10
71	MicroRNA exporter HuR clears the internalized pathogens by promoting pro-inflammatory response in infected macrophages. <i>EMBO Molecular Medicine</i> , 2020 , 12, e11011	12	10
70	The Phenotype of Circulating Neutrophils during Visceral Leishmaniasis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017 , 97, 767-770	3.2	10
69	Comparative Analysis of Cellular Immune Responses in Treated <i>Leishmania</i> Patients and Hamsters against Recombinant Th1 Stimulatory Proteins of <i>Leishmania donovani</i> . <i>Frontiers in Microbiology</i> , 2016 , 7, 312	5.7	10
68	Development of a Multiplexed Assay for Detection of and Protein Biomarkers in Urine Samples of Patients with Visceral Leishmaniasis. <i>Journal of Clinical Microbiology</i> , 2019 , 57,	9.7	9
67	Epitope-Binding Characteristics for Risk versus Protective DRB1 Alleles for Visceral Leishmaniasis. <i>Journal of Immunology</i> , 2018 , 200, 2727-2737	5.3	9
66	Post-kala-azar dermal leishmaniasis (PKDL) in visceral leishmaniasis-endemic communities in Bihar, India. <i>Tropical Medicine and International Health</i> , 2012 ,	2.3	9

65	Over-Expression of Cysteine Leucine Rich Protein Is Related to SAG Resistance in Clinical Isolates of <i>Leishmania donovani</i> . <i>PLoS Neglected Tropical Diseases</i> , 2015 , 9, e0003992	4.8	9
64	Setting Our Sights on Infectious Diseases. <i>ACS Infectious Diseases</i> , 2020 , 6, 3-13	5.5	9
63	Exploring the inhibitory activity of Withaferin-A against Pteridine reductase-1 of <i>L. donovani</i> . <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2016 , 31, 1029-37	5.6	8
62	Efficacy and Safety of Paromomycin in Treatment of Post-Kala-Azar Dermal Leishmaniasis. <i>ISRN Parasitology</i> , 2014 , 2014, 548010		8
61	Health & Demographic Surveillance System profile: the Muzaffarpur-TMRC Health and Demographic Surveillance System. <i>International Journal of Epidemiology</i> , 2014 , 43, 1450-7	7.8	8
60	Tumor necrosis factor alpha neutralization has no direct effect on parasite burden, but causes impaired IFN- γ production by spleen cells from human visceral leishmaniasis patients. <i>Cytokine</i> , 2016 , 85, 184-90	4	8
59	Novel Antigen Detection Assay to Monitor Therapeutic Efficacy of Visceral Leishmaniasis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016 , 95, 800-802	3.2	8
58	<i>Leishmania donovani</i> evades Caspase 1 dependent host defense mechanism during infection. <i>International Journal of Biological Macromolecules</i> , 2019 , 126, 392-401	7.9	8
57	Visceral Leishmaniasis in the Muzaffarpur Demographic Surveillance Site: A Spatiotemporal Analysis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018 , 99, 1555-1561	3.2	7
56	Recuperating Biopharmaceutical Aspects of Amphotericin B and Paromomycin Using a Chitosan Functionalized Nanocarrier via Oral Route for Enhanced Anti-leishmanial Activity. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020 , 10, 570573	5.9	7
55	A molecular signature for CD8 T cells from visceral leishmaniasis patients. <i>Parasite Immunology</i> , 2019 , 41, e12669	2.2	6
54	Post kala azar dermal leishmaniasis and leprosy prevalence and distribution in the Muzaffarpur health and demographic surveillance site. <i>PLoS Neglected Tropical Diseases</i> , 2019 , 13, e0007798	4.8	6
53	Human Papillomavirus Genome based Detection and Typing: A Holistic Molecular Approach. <i>Current Molecular Medicine</i> , 2019 , 19, 237-246	2.5	6
52	Why do Patients in Pre-Anti Retroviral Therapy (ART) Care Default: A Cross-Sectional Study. <i>Indian Journal of Community Medicine</i> , 2016 , 41, 241-4	0.8	6
51	Recombinant <i>Leishmania</i> Rab6 (rLdRab6) is recognized by sera from visceral leishmaniasis patients. <i>Experimental Parasitology</i> , 2016 , 170, 135-147	2.1	6
50	Mutations in an Aquaglyceroporin as a Proven Marker of Antimony Clinical Resistance in the Parasite <i>Leishmania donovani</i> . <i>Clinical Infectious Diseases</i> , 2021 , 72, e526-e532	11.6	6
49	Interleukin 2 is an Upstream Regulator of CD4+ T Cells From Visceral Leishmaniasis Patients With Therapeutic Potential. <i>Journal of Infectious Diseases</i> , 2019 , 220, 163-173	7	5
48	SWATH-MS based quantitative proteomics analysis to evaluate the antileishmanial effect of Commiphora wightii- Guggul and Amphotericin B on a clinical isolate of <i>Leishmania donovani</i> . <i>Journal of Proteomics</i> , 2020 , 223, 103800	3.9	5

47	Improvising anti-leishmanial activity of amphotericin B and paromomycin using co-delivery in d-βocopheryl polyethylene glycol 1000 succinate (TPGS) tailored nano-lipid carrier system. <i>Chemistry and Physics of Lipids</i> , 2020 , 231, 104946	3.7	5
46	Clinical Abacavir Hypersensitivity Reaction among Children in India. <i>Indian Journal of Pediatrics</i> , 2016 , 83, 855-8	3	5
45	Association of interleukin-18 gene polymorphism with susceptibility to visceral leishmaniasis in endemic area of Bihar, an Indian population. <i>Scientific World Journal, The</i> , 2014 , 2014, 852104	2.2	5
44	<i>Leishmania donovani</i> : immunostimulatory cellular responses of membrane and soluble protein fractions of splenic amastigotes in cured patient and hamsters. <i>PLoS ONE</i> , 2012 , 7, e30746	3.7	5
43	Effectiveness of Single-Dose Liposomal Amphotericin B in Visceral Leishmaniasis in Bihar. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019 , 101, 795-798	3.2	5
42	Domestic mammals as reservoirs for <i>Leishmania donovani</i> on the Indian subcontinent: Possibility and consequences on elimination. <i>Transboundary and Emerging Diseases</i> , 2021 ,	4.2	5
41	Integrating genomics and proteomics permits identification of immunodominant antigens associated with drug resistance in human visceral leishmaniasis in India. <i>Experimental Parasitology</i> , 2017 , 176, 30-45	2.1	4
40	Combined neutralization of interferon gamma and tumor necrosis factor alpha induces IL-4 production but has no direct additive impact on parasite burden in splenic cultures of human visceral leishmaniasis. <i>PLoS ONE</i> , 2018 , 13, e0199817	3.7	4
39	Immunological consequences of stress-related proteins--cytosolic trypanothione peroxidase and chaperonin TCP20--identified in splenic amastigotes of <i>Leishmania donovani</i> as Th1 stimulatory, in experimental visceral leishmaniasis. <i>Parasitology</i> , 2015 , 142, 728-44	2.7	4
38	Abnormal B-Cell Subset and Blimp-1-Mediated Humoral Responses Associated With Visceral Leishmaniasis Pathogenesis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019 , 100, 816-821	3.2	4
37	Sensible graphene oxide differentiates macrophages and : a bio-nano interplay in attenuating intracellular parasite.. <i>RSC Advances</i> , 2020 , 10, 27502-27511	3.7	4
36	Hepcidin mediated iron homeostasis as immune regulator in visceral leishmaniasis patients. <i>Parasite Immunology</i> , 2019 , 41, e12601	2.2	4
35	Particle induced X-ray emission study of blood samples of Indian Kala-azar patients. <i>Journal of Parasitic Diseases</i> , 2017 , 41, 193-198	1.3	3
34	Therapeutic Leishmaniasis: Recent Advancement and Developments in Nanomedicines 2019 , 195-220		3
33	Carboxymethyl chitosan modified lipid nanoformulations as a highly efficacious and biocompatible oral anti-leishmanial drug carrier system.. <i>International Journal of Biological Macromolecules</i> , 2022 , 204, 373-385	7.9	3
32	Study the drug adherence and possible factor influencing drug adherence in HIV/AIDS patients in north eastern part of India. <i>Journal of Education and Health Promotion</i> , 2014 , 3, 31	1.4	3
31	Cloning, Expression and Purification of Specific Antigen for Serodiagnosis of Visceral Leishmaniasis. <i>Journal of Molecular Biomarkers & Diagnosis</i> , 2013 , 4, 1000141	2	3
30	Assessing Skin Parasite Load: A Proof of Concept Study of a Microbiopsy Device in an Indian Setting. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021 , 11, 645121	5.9	3

29	Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 1463-1473	6.2	3
28	HLA-DR Class II expression on myeloid and lymphoid cells in relation to HLA-DRB1 as a genetic risk factor for visceral leishmaniasis. <i>Immunology</i> , 2019 , 156, 174-186	7.8	3
27	Nanodiagnosics in leishmaniasis: A new frontiers for early elimination. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2021 , 13, e1675	9.2	3
26	IL-10 and TGF- β -Induced Arginase Expression Contributes to Deficient Nitric Oxide Response in Human Visceral Leishmaniasis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020 , 10, 614165	5.9	3
25	Refining wet lab experiments with in silico searches: A rational quest for diagnostic peptides in visceral leishmaniasis. <i>PLoS Neglected Tropical Diseases</i> , 2019 , 13, e0007353	4.8	2
24	Molecular, biochemical characterization and assessment of immunogenic potential of cofactor-independent phosphoglycerate mutase against <i>Leishmania donovani</i> : a step towards exploring novel vaccine candidate. <i>Parasitology</i> , 2018 , 145, 508-526	2.7	2
23	Suppression of host PTEN gene expression for <i>Leishmania donovani</i> survival in Indian visceral leishmaniasis. <i>Microbes and Infection</i> , 2016 , 18, 369-72	9.3	2
22	Identification and Functional Validation of a Biomarker for the Diagnosis of Miltefosine Relapse during Visceral Leishmaniasis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018 , 98, 492-496	3.2	2
21	Amphiregulin in cellular physiology, health, and disease: Potential use as a biomarker and therapeutic target. <i>Journal of Cellular Physiology</i> , 2021 ,	7	2
20	Short-Course Treatment With Imipramine Entrapped in Squalene Liposomes Results in Sterile Cure of Experimental Visceral Leishmaniasis Induced by Antimony Resistant With Increased Efficacy. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020 , 10, 595415	5.9	2
19	Anti-Interleukin-10 Unleashes Transcriptional Response to Leishmanial Antigens in Visceral Leishmaniasis Patients. <i>Journal of Infectious Diseases</i> , 2021 , 223, 517-521	7	2
18	IFN- γ /CD4T cell-driven prophylactic potential of recombinant LDBPK_252400 hypothetical protein of <i>Leishmania donovani</i> against visceral leishmaniasis. <i>Cellular Immunology</i> , 2021 , 361, 104272	4.4	2
17	Human papillomavirus infection & anal cytological abnormalities in HIV-positive men in eastern India. <i>BMC Infectious Diseases</i> , 2018 , 18, 692	4	2
16	Exploiting knowledge on pharmacodynamics-pharmacokinetics for accelerated anti-leishmanial drug discovery/development. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019 , 15, 595-612	5.5	1
15	Emerging role of $\gamma\delta$ cells in protozoan infection and their potential clinical application.. <i>Infection, Genetics and Evolution</i> , 2022 , 98, 105210	4.5	1
14	A Novel Bioimpedance-Based Detection of Miltefosine Susceptibility Among Clinical Isolates of the Indian Subcontinent Exhibiting Resistance to Multiple Drugs.. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021 , 11, 768830	5.9	1
13	An Insight Into Systemic Immune Response in Mediated Atypical Cutaneous Leishmaniasis in the New Endemic State of Himachal Pradesh, India.. <i>Frontiers in Immunology</i> , 2021 , 12, 765684	8.4	1
12	Isolation and characterisation of <i>Leishmania donovani</i> protein antigens from urine of visceral leishmaniasis patients. <i>PLoS ONE</i> , 2020 , 15, e0238840	3.7	1

11	The drug resistance mechanisms in <i>Leishmania donovani</i> are independent of immunosuppression. <i>Cytokine</i> , 2021 , 145, 155300	4	1
10	Four layer multi-omics reveals molecular responses to aneuploidy in <i>Leishmania</i>		1
9	Clinical profile and response to first-line ARV in HIV patients from Eastern UP and Bihar: a retrospective study. <i>Journal of the Association of Physicians of India, The</i> , 2013 , 61, 239-43	0.4	1
8	Utility of Blood as the Clinical Specimen for the Molecular Diagnosis of Post-Kala-Azar Dermal Leishmaniasis. <i>Journal of Clinical Microbiology</i> , 2021 , 59, e0013221	9.7	0
7	An In-depth Proteomic Map of <i>Leishmania donovani</i> Isolate from Post Kala-azar Dermal Leishmaniasis (PKDL) Patient.. <i>Acta Parasitologica</i> , 2022 , 1	1.7	
6	Herbal Medicines for Thyroid Diseases. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2021 , 256-270.2		
5	Febrifugine dihydrochloride as a new oral chemotherapeutic agent against visceral leishmaniasis infection.. <i>Experimental Parasitology</i> , 2022 , 108250	2.1	
4	Post kala azar dermal leishmaniasis and leprosy prevalence and distribution in the Muzaffarpur health and demographic surveillance site 2019 , 13, e0007798		
3	Post kala azar dermal leishmaniasis and leprosy prevalence and distribution in the Muzaffarpur health and demographic surveillance site 2019 , 13, e0007798		
2	Post kala azar dermal leishmaniasis and leprosy prevalence and distribution in the Muzaffarpur health and demographic surveillance site 2019 , 13, e0007798		
1	Post kala azar dermal leishmaniasis and leprosy prevalence and distribution in the Muzaffarpur health and demographic surveillance site 2019 , 13, e0007798		